First-pass extracted concept

Integrated bioinformatics-guided antigen selection framework

Candidate: workflow template1 source documents3 linked claims1 workflow observations3 stage observations3 step observations

Jump to workflow stages Jump to workflow logic Jump to workflow steps Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Workflow Stage Observations

Stage 1in silico filterin silicoSource 1DOI PubMed

Multi-omics antigen discovery and repertoire expansion

Why this stage exists: The review states that traditional E6/E7 targets are limited by heterogeneous tumor expression and advocates inclusion of tumor-specific neoantigens.

Selection basis: Use multi-omics analysis to identify and broaden candidate antigens beyond traditional E6/E7 targets.

Advance criteria: Candidates proceed if supported as plausible therapeutic antigens within the expanded repertoire.

Enriches for: expanded antigen repertoire, tumor specificity, expression evidence

Guards against: overreliance on heterogeneous E6/E7 expression

Stage 2broad screenin silicoSource 1DOI PubMed

Computational immunogenicity prioritization

Why this stage exists: The review identifies these parameters as key selection criteria and frames immunogenicity prediction as a central part of the framework.

Selection basis: Rank antigens using clonality, expression level, MHC binding affinity, MHC binding stability, and immunogenic potential.

Advance criteria: Candidates advance when they satisfy prioritized antigen-selection parameters.

Higher fidelity: yes

Enriches for: clonality, expression, MHC binding affinity, MHC binding stability, immunogenic potential

Preserves downstream axes: vaccine relevance, broader therapeutic effectiveness

Stage 3functional characterizationin silicoSource 1DOI PubMed

Vaccine design and optimization

Why this stage exists: The framework explicitly spans vaccine design, and the review proposes standardized selection criteria and optimization strategies as a roadmap for more potent and broadly effective vaccines.

Selection basis: Use prioritized antigens to guide next-generation therapeutic vaccine design and optimization strategies.

Advance criteria: Designs are favored when they incorporate prioritized antigens under standardized selection logic.

Higher fidelity: yes

Enriches for: potency, broad effectiveness

Workflow Logic

Workflow evidenceSource 1

Objective: Prioritize therapeutic HPV vaccine antigens and support vaccine design using an integrated bioinformatics framework.

Why it works: The review presents antigen selection as a central determinant of clinical translation and proposes integrating molecular profiling with computational prioritization and design so candidates are filtered using multiple relevance criteria rather than a single antigen class.

Priority logic: The framework first broadens the candidate antigen repertoire beyond canonical E6/E7 targets, then evaluates candidates using standardized parameters such as clonality, expression, MHC binding, stability, and immunogenic potential before vaccine design.

Target properties: antigen clonality, expression level, MHC binding affinity, MHC binding stability, immunogenic potential, vaccine efficacy breadth

Target mechanisms: selection of tumor-associated antigens with stronger and broader immune relevance, prioritization of antigens likely to be presented by MHC and elicit immune responses

Target techniques: multi-omics analysis, immunogenicity prediction, computational antigen prioritization, vaccine design

Workflow Step Observations

Step 1analysisSource 1

Expand candidate antigens beyond canonical E6/E7 targets

Purpose: Address limitations of relying only on traditional HPV antigens by considering additional tumor-specific candidates including neoantigens.

Why now: The review first motivates repertoire expansion because heterogeneous tumor expression limits the traditional E6/E7 strategy.

Targets properties: antigen diversity, tumor specificity, expression support

Step 2analysisSource 1

Prioritize candidates using immunogenicity-related selection parameters

Purpose: Narrow the expanded antigen list using standardized criteria linked to likely therapeutic relevance.

Why now: After broad candidate discovery, computational prioritization is used to rank candidates before vaccine design.

Targets properties: clonality, expression level, MHC binding affinity, MHC binding stability, immunogenic potential

Step 3designSource 1

Use prioritized antigens to guide vaccine design

Purpose: Translate prioritized antigen choices into next-generation therapeutic vaccine designs.

Why now: Vaccine design follows candidate prioritization so the final construct is based on antigens selected using the proposed framework.

Targets properties: potency, broad effectiveness

Evidence Snippets

Central is a bioinformatics-guided antigen selection framework spanning multi-omics analysis, immunogenicity prediction, and vaccine design.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1review2026MEDDOI PubMed

1 evidence snippet 1 workflow logic note 3 workflow stages 3 workflow steps 3 linked claims Claim 1 Claim 2 Claim 3 Multi-omics antigen discovery and repertoire expansion Computational immunogenicity prioritization

Linked Claims

Claim 1selection criteriasupports2026Source 1DOI PubMed

Key antigen selection parameters include antigen clonality, expression level, MHC binding affinity and stability, and immunogenic potential.

Claim 2standardization goalsupports2026Source 1DOI PubMed

Standardized selection criteria and optimization strategies are proposed to improve potency and breadth of therapeutic HPV vaccines.

Claim 3workflow scopesupports2026Source 1DOI PubMed

A bioinformatics-guided antigen selection framework for therapeutic HPV vaccines spans multi-omics analysis, immunogenicity prediction, and vaccine design.